Arsenic in Acute Leukemia Treatment and Environmental Toxicity
This community investigates the dual role of arsenic compounds: their use as targeted agents in treating acute myeloid leukemia and their effects as environmental toxins in drinking water and other exposures.
The research focuses heavily on acute promyelocytic leukemia and acute myeloid leukemia, with arsenic trioxide and sodium arsenite serving as primary therapeutic agents. Key mechanisms under study include oxidative stress, apoptosis, and signaling pathways such as retinoic acid and DNA methylation. A significant portion of the work examines arsenic exposure through drinking water and its resulting toxicity, including arsenic-induced cancer in breast, lung, and liver tissues. The literature frequently involves case reports of newly diagnosed patients and experimental models using rats and mice to assess treatment efficacy and toxicological outcomes.
The largest share of the community's output is found in arsenic research, accounting for 8.5% of all arsenic research, and 14,102 papers here. This element also leads in raw paper count within the group.
The community comprises 21,976 papers, publishing most frequently in Blood, Environmental Health Perspectives, and Toxicology and Applied Pharmacology.
Recent work continues to focus on acute myeloid leukemia management, including consensus documents on minimal residual disease and targeted therapies like quizartinib and revumenib. There is also emerging research on pretargeted mitochondrial delivery of organoarsenicals for cancer immunotherapy.